Is Real-time CGM Superior to Flash Glucose Monitoring
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)Device: Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)
- Registration Number
- NCT04358263
- Lead Sponsor
- Charles University, Czech Republic
- Brief Summary
The aim of the investigator's study is to compare real-time continuous glucose monitoring and flash glucose monitoring in adult patients with Type 1 Diabetes during 4-day training program focused on physical activity and over 4 weeks of follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- patients with T1D naive to rtCGM and isCGM
- Type 1 diabetes for >2 years
- ≥ 18 years old
- CSII or MDI
- GOLD score < 4, no history of severe hypoglycemia within last 6 month
- written informed consent prior to starting study related activity
- severe noncompliance
- severe diabetic retinopathy and/or macular edema
- lactation, pregnancy, intending to become pregnant during study
- condition likely to require MRI
- use of acetaminophen-containing medication
- unwillingness to use the study device for >70% of time
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description rtCGM Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring) Patients with use of the Guardian Connect Mobile system (real-time continuous glucose monitoring). isCGM Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring) Patients with use of the FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring).
- Primary Outcome Measures
Name Time Method Percentage of time in hypoglycemic ranges Up to 2 months \<3,9 mmol/L (70 mg/dl) and \<3,0 mmol/L (54 mg/dl)
- Secondary Outcome Measures
Name Time Method Changes in glycemic variability Up to 2 months Expressed as the coefficient of variation
Percentage of time in hyperglycemic ranges Up to 2 months (\>10,0 mmol/L (180 mg/dl) and \>13,9 mmol/L (250 mg/dl)
Mean sensor glucose concentration Up to 2 months Measured by rtCGM or isCGM
Changes in glycated haemoglobin (HbA1c) Up to 2 months Differences between HbA1c values in the initial period and after follow-up and differences of HbA1c between groups.
Percentage of time in target ranges Up to 2 months 3,9-10,0 mmol/L (70-180 mg/dl)
Changes in quality of life as assessed by validated questionnaire Up to 2 months Assessed by The World Health Organization Quality of Life (WHOQOL)-BREF (Field Trial Version).
This questionnaire contains in total 26 questions in four Domains (Physical health, Psychological health, Social relationships, Environment). Scores in total range between 4-20 (each Domain 0-5), higher scores denote higher quality of life.Incidence of severe hypoglycaemia Up to 2 months Requiring third-party assistance to treat
Trial Locations
- Locations (1)
3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University
🇨🇿Prague, Czech Republic, Czechia